Nuwellis Appoints John L. Erb as Interim CFO

Nuwellis ( (NUWE) ) just unveiled an update.

On October 7, 2025, Robert B. Scott announced his resignation as Chief Financial Officer of Nuwellis, Inc., effective around October 24, 2025. His departure is not due to any disagreements with the company. The company plans to initiate a search for a new CFO. On October 8, 2025, the Board appointed John L. Erb, the current President and CEO, as interim CFO starting on the separation date. Mr. Erb has extensive experience in the medical device industry and has held various leadership roles within Nuwellis and other companies. His appointment as interim CFO is not accompanied by any additional compensation or changes to his current plans.

The most recent analyst rating on (NUWE) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.

Spark’s Take on NUWE Stock

According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.

Nuwellis’ overall stock score is primarily impacted by its financial challenges, including ongoing losses and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are weak due to a negative P/E ratio. While recent corporate events and strategic initiatives offer some promise, the immediate financial outlook remains concerning.

To see Spark’s full report on NUWE stock, click here.

More about Nuwellis

Nuwellis, Inc. is a company involved in the medical device industry, focusing on the development, manufacturing, and distribution of devices for treating congestive heart failure and other heart-related conditions.

Average Trading Volume: 924,849

Technical Sentiment Signal: Sell

Current Market Cap: $3.19M

Find detailed analytics on NUWE stock on TipRanks’ Stock Analysis page.